Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 23, 2017
Pharmacy Choice - News - Generic Drugs - June 23, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 221     Next >>     Go To Page:

6/16/17 - Aspen loses Italy appeal over cancer drug prices
The Italian case relates to the prices of a portfolio of off-patent cancer drugs that Aspen acquired from GlaxoSmithKline several years ago, and that it recently increased. On Tuesday, the South African Competition Commission said it was launching an investigation into the price of cancer drugs, homing in on Aspen and multinational pharmaceutical..
6/16/17 - CBO Issues Cost Estimate for FDA Reauthorization Act
*Reauthorize certain programs and grants administered by FDA and the National Institutes of Health,. *Require the Government Accountability Office to report on FDA and NIH. Implementing S. 934 would require increased funding for a variety of FDA activities, but most of the increase in FDA spending would be offset by additional fees that would be co
6/16/17 - Findings from Winthrop University Hospital Provides New Data on Human Growth Hormone (Ten years of biosimilar recombinant human growth hormone in...
The news correspondents obtained a quote from the research from Winthrop University Hospital, "A biosimilar is defined by the European Medicines Agency as a biological medicine that is similar to another biological medicine that has already been authorized for use. The EMA led the way in developing the biosimilar concept, and the type of science-ba
6/16/17 - Findings on Cancer Risk Described by M.V. Borras Perez and Colleagues (Ten years of clinical experience with biosimilar human growth hormone: a...
Findings on Cancer Risk Described by M.V. Borras Perez and Colleagues. By a News Reporter-Staff News Editor at Drug Week Fresh data on Oncology- Cancer Risk are presented in a new report. According to news reporting out of Granollers, Spain, by NewsRx editors, research stated, "Safety concerns for recombinant human growth hormone treatments inclu
6/16/17 - Highlighting Bipartisan Plan to Lower Cost of Prescription Drugs, Collins, McCaskill Praise Food and Drug Administration Chief's Remarks
Washington, D.C.- U.S. Senators Susan Collins and Claire McCaskill were encouraged by recent remarks by the head of the Food and Drug Administration in support of solutions to help keep prescription drugs affordable and improve patients' access to medication, echoing the Senators' bipartisan efforts. "We share your commitment to increasing generic
6/16/17 - Key Themes Centred Around Regulation and New Market Dynamics at 8th Annual Biosimilars Industry Summit
Biosimilars 2017 draws from European experience to unveil new market access and commercialisation strategies for an evolving pharmaceutical landscape.
6/16/17 - Lannett Announces Approval For Amantadine Hydrochloride Capsules USP, 100 mg
Lannett Company, Inc. today announced that it received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Amantadine Hydrochloride Capsules USP, 100 mg, the therapeutic equivalent to the reference standard drug, Amantadine Hydrochloride Capsules USP, 100 mg, of Sandoz Pharmaceuticals. For the 12 months
6/16/17 - LUPIN LAUNCHES ANTIDEPRESSANT TABLETS IN US
Lupin, the drug manufacturer, has launched its antidepressant Bupropion Hydrochloride extended release tablets in the USA. The company had received approval from the United States Food and Drug Administration to launch these drugs. The drugs are generic versions of Wellbutrin XL tablets of Valeant Pharmaceuticals North America LLC.
6/16/17 - Lupin Launches Generic Antidepressant In The US [T-break Tech (Middle East)]
Wellbutrin XL tablet has yearly US sales of USD 758 million or about Rs 5,000 cr. Lupin is the 6 largest generics pharmaceutical company by sales globally and the second biggest pharma company in India. It focuses on Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-infective and NSAID space and has sales of 171,198 million per year.
6/16/17 - Mylan Launches Generic Azilect Tablets
By a News Reporter-Staff News Editor at Drug Week Mylan N.V. announced the U.S. launch of Rasagiline Tablets, 0.5 mg and 1 mg, a generic version of the reference listed drug, Teva's Azilect Tablets. Rasagiline Tablets, 0.5 mg and 1 mg, had U.S. sales of approximately $343 million for the 12 months ending March 31, 2017, according to QuintilesI
6/16/17 - Mylan Launches Generic Reclast Injection
By a News Reporter-Staff News Editor at Drug Week Mylan N.V. announced the U.S. launch of Zoledronic Acid Injection, 5 mg/100 mL Single Dose Vial, a generic version of Novartis' Reclast Injection. Zoledronic Acid Injection, 5 mg/100 mL Single Dose Vial, had U.S. sales of approximately $22.1 million for the 12 months ending March 31, 2017, acco
6/16/17 - Researchers from Comenius University in Bratislava Discuss Findings in Cardiovascular Agents (Fast Ultra High Performance Liquid Chromatography With...
Researchers from Comenius University in Bratislava Discuss Findings in Cardiovascular Agents. According to news reporting originating in Bratislava, Slovakia, by NewsRx journalists, research stated, "Tadalafil is used for the treatment of erectile dysfunction and its related patents expired in 2016, therefore related generic drugs production is...
6/16/17 - S/Africa probes multinationals for overpricing drugs [Agence de Presse Africaine]
According to Bonakele on Thursday, the investigation into three multinationals is probing US-based biotechnology company Roche Holding AG, US-based pharmaceutical corporation Pfizer and generic drug makers Aspen Pharmacare. Bonakele said they had reason to believe Roche's breast cancer medication known as Herceptin and Herclon were priced...
6/16/17 - Studies from Sandoz Reveal New Findings on Drug Development (Ten years of biosimilars in Europe: development and evolution of the regulatory pathways)
By a News Reporter-Staff News Editor at Drug Week Research findings on Drugs and Therapies- Drug Development are discussed in a new report. According to news reporting out of Kundl, Austria, by NewsRx editors, research stated, "A biosimilar is defined by the European Medicines Agency as a biological medicine that is similar to another biological
6/16/17 - Studies from Semmelweis University Describe New Findings in Crohn's Disease (Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab...
According to news reporting originating in Budapest, Hungary, by NewsRx journalists, research stated, "Biosimilar infliximab CT-P13 received European Medicines Agency approval in June 2013 for all indications of the originator product. In the present study, we aimed to evaluate the predictors of short-and medium-term clinical outcome in patients tr
6/15/17 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Animal Generic Drug User Fee Act...
All comments should be identified with the OMB control number 0910-0632. Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Form FDA 3728, Animal Generic
6/15/17 - Aimed Alliance Says Congress Needs the Complete Facts About The Nation's Risk Evaluation and Mitigation Strategies (REMS) Program
Because REMS programs make it possible for millions of Americans with diseases like cancer, HIV, kidney disease, and multiple sclerosis access to be treated with valuable therapies that would otherwise not be on the market today, the Aimed Alliance is urging policymakers to get the complete facts so lawmakers will recognize the meaningful impact of
6/15/17 - Baxter Announces Agreement With Dorizoe Lifesciences to Further Expand Generic Injectables Pipeline
Baxter International, a health care company that focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions, issued the following news release:. Baxter International Inc., a global medical products company, today announced an agreement with Dorizoe Lifesciences Limited, a full-service gl
6/15/17 - Baxter Announces Agreement with Dorizoe Lifesciences to Further Expand Generic Injectables Pipeline; Collaboration builds upon Baxter's pending acquisition of Claris and its ScinoPharm collaboration and advances Baxter's strategy of becoming a le
DEERFIELD, Ill.- Baxter International Inc., a global medical products company, today announced an agreement with Dorizoe Lifesciences Limited, a full-service global contract research and development organization, that will facilitate accelerated development of more than 20 generic injectable products-including anti-infectives, oncolytics and...
6/15/17 - Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA [Syrian Arab News Agency]
Boehringer Ingelheim announced today results from the pivotal Phase III VOLTAIRE-RA1 study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European...
6/15/17 - Cancer drug price increases within allowable limits, says Aspen [Sudan Tribune]
The three Aspen Pharmacare cancer medicines being probed by the Competition Commission have a collective annual turnover of just R3m, and have never seen price increases outside the regulatory framework overseen by the health department, the company said on Wednesday. The commission announced on Tuesday that it was investigating the price of cancer
6/15/17 - Celltrion biosimilar proves effectiveness in lymphoma and rheumatoid arthritis [Tehran Times (Iran)]
The drugs effectiveness in treating FL was shown through data presented at the International Conference on Malignant Lymphoma. Our studies consistently demonstrate the equivalence and comparability of our biosimilar rituximab, CT-P10, to reference rituximab, explained Dr Kwon, Medical Director at Celltrion Healthcare. Dr Dae-Hyun Yoo, Global Princi
6/15/17 - FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus
Novartis International AG/ FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus . *FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus* Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine* Sandoz looks forward to working with F
6/15/17 - Global Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025 : Credence Research
Credenceresearch.com has announced the addition of "Global Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025" Market Research Report to their Database. The latest market report published by Credence Research, Ltd. "Global Biosimilars Market- Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2017- 2025,"
6/15/17 - GNW-News: FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus (english)
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus . Novartis International AG/ FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus . *FDA accepts Sandoz ANDA for substitutable generic version of Advair.
Articles(s): 1 - 25 of 221     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415